BRIEF-Sanofi Says Phase 2B Study Shows duvakitug Efficacious In Ulcerative Colitis, Crohn's Disease

Reuters

02/17

BRIEF-<a href="https://laohu8.com/S/GCVRZ">Sanofi</a> Says Phase 2B Study Shows duvakitug Efficacious In Ulcerative Colitis, Crohn's Disease

Feb 17 (Reuters) - Sanofi SA SASY.PA:

SANOFI AND TEVA’S DUVAKITUG PHASE 2B MAINTENANCE DATA DEMONSTRATED CLINICALLY MEANINGFUL DURABLE EFFICACY IN ULCERATIVE COLITIS AND CROHN’S DISEASE
DUVAKITUG WAS WELL TOLERATED AND SAFETY WAS CONSISTENT WITH THE INDUCTION STUDY
FINDINGS REINFORCE POTENTIAL OF DUVAKITUG WHICH IS IN ONGOING PHASE 3 PROGRAMS IN UC AND CD

Source text: ID:nGNX1S0ckx

Further company coverage: SASY.PA

(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2612456940"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612456940\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612456940?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-17 19:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612456940","market":"fut","top_or_hot":-1,"title":"BRIEF-Sanofi Says Phase 2B Study Shows duvakitug Efficacious In Ulcerative Colitis, Crohn's Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> Says Phase 2B Study Shows duvakitug Efficacious In Ulcerative Colitis, Crohn's Disease</title></head><body><p><span>Feb 17 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> SA <span>SASY.PA</span>:</p><ul><li><p>SANOFI AND TEVA’S DUVAKITUG PHASE 2B MAINTENANCE DATA DEMONSTRATED CLINICALLY MEANINGFUL DURABLE EFFICACY IN ULCERATIVE COLITIS AND CROHN’S DISEASE</p></li><li><p>DUVAKITUG WAS WELL TOLERATED AND SAFETY WAS CONSISTENT WITH THE INDUCTION STUDY</p></li><li><p>FINDINGS REINFORCE POTENTIAL OF DUVAKITUG WHICH IS IN ONGOING PHASE 3 PROGRAMS IN UC AND CD</p></li></ul><p>Source text: <span>ID:nGNX1S0ckx</span></p><p>Further company coverage: <span>SASY.PA</span></p><p> (Gdansk Newsroom)</p><p> ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Sanofi Says Phase 2B Study Shows duvakitug Efficacious In Ulcerative Colitis, Crohn's Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Sanofi Says Phase 2B Study Shows duvakitug Efficacious In Ulcerative Colitis, Crohn's Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-17 19:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> Says Phase 2B Study Shows duvakitug Efficacious In Ulcerative Colitis, Crohn's Disease</title></head><body><p><span>Feb 17 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> SA <span>SASY.PA</span>:</p><ul><li><p>SANOFI AND TEVA’S DUVAKITUG PHASE 2B MAINTENANCE DATA DEMONSTRATED CLINICALLY MEANINGFUL DURABLE EFFICACY IN ULCERATIVE COLITIS AND CROHN’S DISEASE</p></li><li><p>DUVAKITUG WAS WELL TOLERATED AND SAFETY WAS CONSISTENT WITH THE INDUCTION STUDY</p></li><li><p>FINDINGS REINFORCE POTENTIAL OF DUVAKITUG WHICH IS IN ONGOING PHASE 3 PROGRAMS IN UC AND CD</p></li></ul><p>Source text: <span>ID:nGNX1S0ckx</span></p><p>Further company coverage: <span>SASY.PA</span></p><p> (Gdansk Newsroom)</p><p> ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUAM4KSY:1","article_id":"2612456940","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612456940","pubTimestamp":1771326599,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Sanofi Says Phase 2B Study Shows duvakitug Efficacious In Ulcerative Colitis, Crohn's DiseaseFeb 17 (Reuters) - Sanofi SA SASY.PA:SANOFI AND TEVA’S DUVAKITUG PHASE 2B MAINTENANCE DATA DEMONSTRAT","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4559":"巴菲特持仓","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4566":"资本集团","TEVA":"梯瓦制药","BK4557":"大麻股","BK4596":"哈里斯概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4584":"避孕概念"},"translate_title":"简介-赛诺菲表示2B期研究显示duvakitug对溃疡性结肠炎、克罗恩病有效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":0.9},"content_text":"BRIEF-Sanofi Says Phase 2B Study Shows duvakitug Efficacious In Ulcerative Colitis, Crohn's DiseaseFeb 17 (Reuters) - Sanofi SA SASY.PA:SANOFI AND TEVA’S DUVAKITUG PHASE 2B MAINTENANCE DATA DEMONSTRATED CLINICALLY MEANINGFUL DURABLE EFFICACY IN ULCERATIVE COLITIS AND CROHN’S DISEASEDUVAKITUG WAS WELL TOLERATED AND SAFETY WAS CONSISTENT WITH THE INDUCTION STUDYFINDINGS REINFORCE POTENTIAL OF DUVAKITUG WHICH IS IN ONGOING PHASE 3 PROGRAMS IN UC AND CDSource text: ID:nGNX1S0ckxFurther company coverage: SASY.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}